Abstract:Repurposing identified Food and Drug Administration‐approved drug‐biomarker combinations with high sensitivity and specificity. In a real‐world dataset, repurposing identified novel drug‐biomarker combinations in patients who were ineligible for standard therapies or biomarker‐matched trials. Preliminary functional validation was demonstrated for two drug‐biomarker combinations. Using The Cancer Genome Atlas data, the potential scope of repurposing was identified. Purpose Systematic repurposing of approved medicines for another indication may accelerate drug development in oncology. We present a strategy combining biomarker testing with drug repurposing to identify new treatments for patients with advanced cancer. Methods Tumours were sequenced with the Illumina TruSight Oncology 500 (TSO‐500) platform or the FoundationOne CDx panel. Mutations were screened by two medical oncologists and pathogenic mutations were categorised referencing literature. Variants of unknown significance were classified as potentially pathogenic using plausible mechanisms and computational prediction of pathogenicity. Gain of function (GOF) mutations were evaluated through repurposing databases Probe Miner (PM), Broad Institute Drug Repurposing Hub (Broad Institute DRH) and TOPOGRAPH. GOF mutations were repurposing events if identified in PM, not indexed in TOPOGRAPH and excluding mutations with a known Food and Drug Administration (FDA)‐approved biomarker. The computational repurposing approach was validated by evaluating its ability to identify FDA‐approved biomarkers. The total repurposable genome was identified by evaluating all possible gene‐FDA drug‐approved combinations in the PM dataset. Results The computational repurposing approach was accurate at identifying FDA therapies with known biomarkers (94%). Using next‐generation sequencing molecular reports (n = 94), a meaningful percentage of patients (14%) could have an off‐label therapeutic identified. The frequency of theoretical drug repurposing events in The Cancer Genome Atlas pan‐cancer dataset was 73% of the samples in the cohort. Conclusion A computational drug repurposing approach may assist in identifying novel repurposing events in cancer patients with no access to standard therapies. Further validation is needed to confirm a precision oncology approach using drug repurposing.

Discovery of Noncancer Drug Effects on Survival in Electronic Health Records of Patients With Cancer: A New Paradigm for Drug Repurposing.

Computational drug repurposing based on electronic health records: a scoping review

Drug Repurposing in Oncology: Current Evidence and Future Direction

Computational repurposing of oncology drugs through off‐target drug binding interactions from pharmacological databases

Overcoming cancer therapeutic bottleneck by drug repurposing

Repurposing non-oncology small-molecule drugs to improve cancer therapy: Current situation and future directions

Drug repurposing against breast cancer by integrating drug-exposure expression profiles and drug–drug links based on graph neural network

Drug repurposing—an emerging strategy in cancer therapeutics

Drug Repurposing: Exploring Potential Anti-Cancer Strategies by Targeting Cancer Signalling Pathways

Artificial intelligence, machine learning, and drug repurposing in cancer

Integrating gene expression and clinical data to identify drug repurposing candidates for hyperlipidemia and hypertension

A systematic analysis of FDA-approved anticancer drugs

DrugReSC: targeting disease-critical cell subpopulations with single-cell transcriptomic data for drug repurposing in cancer

DrugRepo: a novel approach to repurposing drugs based on chemical and genomic features

The landscape of the methodology in drug repurposing using human genomic data: a systematic review

A drug repurposing method based on inhibition effect on gene regulatory network

Repositioning Drugs For Breast Cancer Based On The Identification Of Cancer Related Signaling Pathways

Drug repurposing screening and mechanism analysis based on human colorectal cancer organoids

Use of Genome-Wide Association Studies for Cancer Research and Drug Repositioning

Revitalizing Cancer Treatment: Exploring the Role of Drug Repurposing

Synergistic Effects of Tranylcypromine and NRF2 inhibitor: A Repurposing Strategy for Effective Cancer Therapy